glp-1 clinical trials near me Medications Clinic in Fayetteville, NC GLP-1 and Addiction: Clinical Trials
Description
The ongoing FLOW trial (NCT03819153) will be the first large multinational randomised placebo-controlled trial to primarily investigate the effects of a GLP1-RA, once-weekly subcutaneous semaglutide, on major kidney outcomes in adults with type 2 diabetes and CKD [50]
Lindsay Gellman is a writer in New York whose work focuses on the business of health
2026 Trends: While exact 2026 national hospital figures are still being tracked, regional research from the University of New Mexico shows that up to 44% of reported GLP-1 exposure cases in 2026 are severe enough to require an immediate emergency room visit.
2025 Jan 23:S0190-9622(25)00126-4
10.1016/j.dsx.2020.03.009 [DOI] [PubMed] [Google Scholar] 5.Caruso I., Cignarelli A., Sorice G.P
